RewordedRisk Factors
Further, if we were to enter into a credit facility or issue debt securities or preferred stock in the future, we may become contractually restricted from paying dividends.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result, we will experience experienced increased compensation costs for certain of our employees and vendors beginning in 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we are unable to successfully compete, our business and financial condition would could be adversely affected.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our substantial debt could adversely affect our financial condition and prevent us from fulfilling our obligations under our outstanding indebtedness.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our current substantial indebtedness and any future indebtedness we incur could adversely affect our financial condition.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our substantial indebtedness could also:
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
As part of our continued strategic expansion in Digital Health, we recently completed three acquisitions: iCAD, Inc., an AI-powered breast health solutions company; See-Mode Technologies, which enhances ultrasound-based diagnostics through artificial intelligence; and CIMAR (UK) Limited, which provides cloud-based medical image storage, PACS, and AI-enabled imaging workflow solutions. We are currently integrating these businesses into our Digital Health segment
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On June 2, 2025, through our wholly owned subsidiary DH AI International Holdings, B.V, we acquired all of the equity interest in See-Mode Technologies (“See-Mode”), a medical technology company focused on using artificial intelligence to enhance ultrasound-based diagnostics.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On July 17, 2025, we completed the acquisition of all of the outstanding equity interests of iCAD, Inc. (“iCAD”), a global leader in AI-powered breast health solutions. The acquisition integrates iCAD’s commercial, technology, and regulatory capabilities with those of DeepHealth, our wholly owned subsidiary within the Digital Health segment. The transaction strengthens DeepHealth’s position as an industry leader in AI-enabled breast cancer image interpretation and workflow optimization and expands its global market reach.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The transaction was accounted for as the acquisition of a business and was completed through an all-stock exchange, with total purchase consideration of approximately $110.7 million based on the fair value of our common stock issued to iCAD shareholders and the fair value of our options issued in exchange for outstanding iCAD options.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
We allocated the purchase price to the assets acquired and liabilities assumed based on their estimated fair values, which resulted in the recognition of goodwill of approximately $36.6 million, primarily reflecting expected synergies from integrating iCAD’s technology portfolio, established customer relationships, and assembled workforce. In addition, we recorded identifiable intangible assets related to backlog, developed technology, customer relationships, and trade name totaling
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
approximately $38.3 million, consisting of $1.8 million, $0.7 million, $6.8 million, and $29.0 million, respectively, deferred tax asset, net of $20.6 million, Cash, deposits and others of $14.2 million, and property and equipment of $1.1 million.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the iCAD acquisition, the Company identified and measured the fair values of acquired intangible assets, including backlog, trade names, developed technology, in-process research and development (“IPR&D”), and customer relationships. The valuations were performed using the income approach, consistent with market participant assumptions. The income approach incorporated assumptions such as projected revenues, estimated customer attrition, royalty rates, and discount rates reflecting market participant expectations. IPR&D projects were determined to have no material fair value as of the acquisition date. The identified intangible assets were assigned estimated useful lives as follows: backlog — approximately 4 years; trade names — approximately 1 year; developed technology — approximately 7 years; and customer relationships — approximately 15 years.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On November 10, 2025, the Company completed the acquisition of all outstanding shares of CIMAR (UK) Limited (“CIMAR”), a United Kingdom–based provider of medical image storage and cloud-based PACS solutions. The acquisition was accounted for as a business combination.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The total purchase consideration was approximately $37.0 million, consisting of $13.2 million in cash, $14.8 million in RadNet common stock issued after year end, a holdback of $3.2 million, and contingent consideration with a fair value of approximately $5.8 million as of the acquisition date, payable upon the achievement of specified recurring revenue targets.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The purchase consideration was preliminarily allocated to the assets acquired and liabilities assumed based on their estimated fair values, resulting in the recognition of goodwill of approximately $20.1 million, which is primarily attributable to expected synergies from integrating CIMAR’s technology and operations with the Company’s Digital Health platform.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
Identifiable intangible assets recognized totaled approximately $22.3 million, consisting primarily of customer relationships of approximately $19.7 million, National Health Service ("NHS") and International Organization for Standardization ("ISO") certifications of approximately $2.2 million, and trade names of approximately $0.5 million. In addition, the Company recorded current net liabilities of approximately $0.3 million. The Company also recognized deferred tax liabilities of approximately $5.7 million in connection with the acquisition..
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The identifiable intangible assets were valued using income- and cost-based valuation methodologies in accordance with ASC 805. Customer relationships were valued using the multi-period excess earnings method, which considers projected revenues, customer attrition, contributory asset charges, and a market-based discount rate. Trade names were valued using the relief-from-royalty method, based on projected revenues, an estimated royalty rate, and a market-based discount rate. NHS and ISO certifications were valued using a cost approach based on estimated replacement cost. The estimated useful lives are approximately 21 years for customer relationships, 4 years for trade names, and 1 years for certifications.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RemovedMD&A
Further, we are using AI to develop solutions that employ machine learning to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care. These AI solutions will initially be focused in the fields of screening for breast, prostate, lung and colon cancers. Our DeepHealth, Inc. subsidiary received FDA clearance for use of its SaigeQ "triage"/workflow product, SaigeDX advanced diagnostic product and Saige-Density breast density assessment software for screening breast mammography, which we have begun to roll out in certain markets as an Enhanced Breast Cancer Detection solution. Our Aidence Holding B.V. subsidiary is developing solutions for interpretation of chest and lung CT scans for lung cancer screening. The Aidence Holding B.V. subsidiary has received the CE marking for these solutions and has existing customers in seven European countries, with its largest concentration in the United Kingdom, and plans to submit an application for FDA clearance to sell in the United States. Our Quantib B.V. subsidiary is primarily focused on interpretation of prostate MRI for widespread prostate cancer screening. Quantib’s prostate MRI post-processing software has both FDA clearances and European CE marking. Our digital health segment provides these solutions to RadNet and to over 400 customers in the United States and Europe.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Entity Date Acquired Total Consideration Property & Equipment Right of Use Assets Goodwill Intangible Assets Other Right of Use Liabilities
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
We grow our imaging center business through a combination of organic growth as well as acquisitions and joint ventures. In the discussion below, the "same center" metrics are based on imaging centers that were in operation throughout the period of January 1, 2023 through December 31, 2024. Excluded amounts relate to imaging centers that were acquired or divested between January 1, 2023 through December 31, 2024.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Consistent with the higher procedure volumes noted above, our staffing levels were adjusted to support the influx of patients seeking radiology procedures. Additionally, we are continuing to face inflation in employee wage rates as we compete for talent in a tight labor market, further impacted by the October 2024 increase in California's minimum wage for healthcare workers.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Building and equipment rental expense on a same center basis was relatively unchanged from the prior period.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The increase in medical supplies expense was driven by our higher patient volume and product shift towards more advanced imaging modalities. The increase in PETHC procedures related to prostate cancer and suspected Alzheimer studies also raised medical supplies expense due to the requirement for high-cost isotope tracers.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Other operating expenses was relatively unchanged compared to the same period in the prior year and lower as a percentage of overall revenues.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
For the year ended December 31, 2023, we recognized a non-recurring gain on the contribution of assets into our Santa Monica Imaging Group LLC joint venture.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
We grow our imaging center business through a combination of organic growth as well as acquisitions and joint ventures. In the discussion below, same center metrics are based on imaging centers that were in operation throughout the period of January 1, 2022 through December 31, 2023. Excluded amounts relate to imaging centers that were acquired or divested between January 1, 2022 through December 31, 2023.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Overall revenue change was driven by procedure volume growth of 5.7% compared to the same period in the prior year. On a same center basis, the increase in revenue was largely attributable to product mix as advanced radiology procedures of MRI, PET, and CT expanded at combined 7.2% to provide the major portion of the revenue growth.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Similar to the prior year, growth in procedure volumes precipitated increases in salary expenses to meet additional professional staffing needs and we increased salaries to retain our skilled work force in the current tight labor market.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in building and equipment rental was the result of our contribution of Phoenix, AZ imaging centers in connection with the formation of the Arizona Diagnostic Radiology Group joint venture in November 2022 and from the buyout of radiology equipment lease contracts during the year.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedMD&A
Common Stockholders $ (18,652) $ 2,793 $ 3,044 $ 10,650 Income taxes 14,862 6,026 8,473 9,361 Interest expense 69,913 79,849 64,483 50,841 Severance costs 3,145 1,902 3,778 946 Depreciation and amortization 152,127 137,838 128,391 115,877 Non-cash employee stock-based compensation 54,601 29,833 26,785 23,770 Loss on sale and disposal of equipment and other 9,658 2,276 2,187 2,529 Non-cash change in fair value of interest rate hedge 7,112 8,006 8,185 (39,621) Other (income) expenses (32,066) (24,916) (6,354) 1,833 Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 20,155 14,995 1,308 — Lease abandonment charges 8,563 2,478 5,146 — Gain on contribution of imaging centers into joint venture — — (16,808) — Loss on extinguishment of debt and related expenses — 11,292 — 731 Legal settlements — — 2,197 Change in estimate related to refund liability — — 8,089 Non-cash change to contingent consideration 110 1,974 (4,075) 47 Acquisition related non-cash intangible adjustment — — 3,950 — Non-operational rent expenses 3,247 4,233 3,629 4,297 Acquisition transaction costs 7,446 880 222 927 Adjusted EBITDA - Radnet, Inc. $300,221 $279,459 $232,344 $192,474 NOTE Adjusted EBITDA - Imaging Center Segment 284,710 264,901 225,846 190,695 Adjusted EBITDA - Digital Health Segment $ 15,511 $ 14,558 $ 6,498 $ 1,779
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Balance Sheet Data as of December 31, 2024 2023 2022 Cash and cash equivalents $ 740,020 $ 342,570 Accounts receivable 185,821 163,707 Working capital (exclusive of current operating lease liability) 596,158 197,805 Stockholders' equity 1,133,410 813,359 Income Statement data for the years ended December 31, 2025 2024 2023 Total revenue $ 2,040,210 $ 1,829,664 $ 1,616,630 $ 1,430,061 Net (loss) income attributable to RadNet RadNet, Inc. common stockholders (18,652) 2,793 3,044 10,650
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Years Ended December 31, 2025 2024 2023 2022 REVENUE Service fee revenue 93.8% 92.5% 90.5% 89.4% Revenue under capitation arrangements 6.2% 7.5% 9.5% 10.6% Total service revenue 100.0% 100.0% 100.0% OPERATING EXPENSES Cost of operations, excluding depreciation and amortization 88.5% 86.4% 86.3% 88.4% Lease abandonment charges 0.4% 0.1% 0.3% —% Depreciation and amortization 7.5% 7.5% 7.9% 8.1% Gain on contribution of imaging centers into joint venture —% —% (1.0)% —% Loss on sale and disposal of equipment 0.5% 0.1% 0.1% 0.2% Severance costs 0.2% 0.1% 0.2% 0.1% Total operating expenses 97.0% 94.3% 93.9% 96.8% INCOME FROM OPERATIONS 3.0% 5.7% 6.1% 3.2% OTHER INCOME AND EXPENSES Interest expense 3.4% 4.4% 4.0% 3.6% Equity in earnings of joint ventures (0.7)% (0.8)% (0.4)% (0.7)% Non-cash change in fair value of interest rate swaps 0.3% 0.4% 0.5% (2.8)% Debt restructuring and extinguishment expenses —% 0.6% —% 0.1% Other income (1.6)% (1.4)% (0.4)% 0.1% Total other expenses 1.5% 3.3% 3.7% 0.3% 3.8% INCOME BEFORE INCOME TAXES 1.6% 2.5% 2.4% 3.0% Provision for income taxes (0.7)% (0.3)% (0.5)% (0.7)% NET INCOME 2.1% 0.8% 2.0% 1.8% 2.3% Net income attributable to noncontrolling interest 1.7% 2.0% 1.7% 1.6% NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Years Ended December 31, 2025 2024 2023 Salaries and professional reading fees, excluding stock-based compensation $ 984,281 1,083,550 $ 853,327 984,280 Stock-based compensation 44,674 26,863 24,574 Building and equipment rental 127,798 121,514 117,405 Medical supplies 126,126 103,189 86,213 Other operating expenses* 275,587 271,672 355,225 303,952 Cost of operations 1,511,434 1,353,191 1,737,373 1,539,798 Depreciation and amortization 136,297 127,142 120,141 Gain on contribution of imaging centers into joint venture — (16,808) Lease abandonment charges 8,563 2,478 5,146 Loss on sale and disposal of equipment 9,821 2,257 2,191 Severance costs 1,797 1,095 1,973 Total operating expenses $ 1,644,406 1,893,851 $ 1,465,834 1,672,770
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in interest expense was the result in the general increase in term loan debt primarily due to the refinancing repricing transaction of our Barclays credit facility Revolving Credit Facility (as defined in April the notes to our consolidated financial statements) in the fourth quarter of 2024, partially offset by which resulted in lower interest rates compared to the same period in the prior year.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Balance Sheet Data as of December 31, 2025 2024 2023 2022 Cash and cash equivalents $ 767,215 $ 740,020 $ 342,570 Accounts receivable 200,317 185,821 163,707 Working capital (exclusive of current operating lease liability) 507,298 596,158 197,805 Stockholders' equity 1,355,886 1,133,410 813,359 Income Statement data for the years ended December 31, Total revenue $ 1,829,664 $ 1,616,630 $ 1,430,061 Net income attributable to RadNet common stockholders 2,793 3,044 10,650
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The portfolio of AI and software solutions is anchored by eRad, Inc.'s RIS/PACS, informatics designed specifically for outpatient radiology Enterprise Operations solutions (traditionally knowns as RIS), Enterprise Imaging solutions (traditionally known as PACS), and Clinical AI solutions, enabled by the DeepHealth OS, a cloud-native operating system that helps operate all connects critical aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The As of December 31, 2025, the valuation of assets acquired and liabilities assumed has not yet been finalized as of December 31, 2024, fair value determination is preliminary and subject to change. change, primarily with respect to the valuation of deferred taxes.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The $12.2 million increase in cash Cash provided by operating financing activities for the year ended December 31, 2024 2025 decreased by $325.7 million compared to the year ended December 31, 2023 was primarily driven by an increase in income from operations. 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by operating activities for the year ended December 31, 2024 2025 included $289.5 $308.6 million in of net income reconciling adjustments income, adjusted for non-cash items such as depreciation and amortization, non-cash lease expense, stock-based compensation and deferred taxes, offset by a $56.5 $9.8 million change in assets and liabilities.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Stock-based compensation increased $2.3 $17.8 million, or 9.3%, 66.3%, to approximately $44.7 million for the year ended December 31, 2025 compared to $26.9 million for the year ended December 31, 2024 compared to $24.6 million for the year ended December 31, 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 Segment net loss $ (30,299) $ (19,925) $ (5,154) $ (6,476) Stock Compensation 9,927 2,971 2,211 2,782 Depreciation & Amortization 15,831 10,696 8,250 6,852 Other operating loss (163) 19 (4) 23 Other income — 5,419 4,537 1,920 Severance 1,348 807 1,805 20 Income taxes (2,011) (424) (1,906) (3,342) Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 20,155 14,995 — — Non-cash change to contingent consideration 710 — (7,191) — Acquisition related to non-cash intangible adjustment — — 3,950 — Adjusted EBITDA - Digital Health Segment $ 15,511 $ 14,558 $ 6,498 $ 1,779
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new